Regional Anesthesia For Surgery — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for regional anesthesia for surgery. 176 active patents protecting 2 drugs from 2+ originators. First major cliff: 2027. Daily refresh.

2
Approved drugs
176
Active US patents
58/100
Avg vulnerability
—
Annual revenue covered

Originators in Regional Anesthesia For Surgery

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Innocoll 108 patents Johnson & Johnson (Janssen Pharmaceutica) 68 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating regional anesthesia for surgery. Each bar = one year. Y-axis scaled to peak year (54 patents).

54
27
14
30
20
34
40
35
4
36
30
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Bupivacaine Hydrochloride And Epinephrine
BUPIVACAINE
 Innocoll 108 64 — 2034-03-13
Duragesic
fentanyl
 Johnson & Johnson (Janssen Pharmaceutica) 68 51 — 2027-01-25

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11844837 Bupivacaine Hydrochloride And Epinephrine method of use 75 2036-04-21
11844837 Bupivacaine Hydrochloride And Epinephrine method of use 75 2036-04-21
11844837 Bupivacaine Hydrochloride And Epinephrine method of use 75 2036-04-21
11844837 Bupivacaine Hydrochloride And Epinephrine method of use 75 2036-04-21
12151024 Bupivacaine Hydrochloride And Epinephrine method of use 75 2041-01-22
12144890 Bupivacaine Hydrochloride And Epinephrine method of use 75 2041-01-22
11925706 Bupivacaine Hydrochloride And Epinephrine method of use 75 2041-01-22
12144890 Bupivacaine Hydrochloride And Epinephrine method of use 75 2041-01-22
12296047 Bupivacaine Hydrochloride And Epinephrine method of use 75 2041-01-22
12296047 Bupivacaine Hydrochloride And Epinephrine method of use 75 2041-01-22

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
10980886 Bupivacaine Hydrochloride And Epinephrine formulation 42 2035-04-20
10980886 Bupivacaine Hydrochloride And Epinephrine formulation 42 2035-04-20
10980886 Bupivacaine Hydrochloride And Epinephrine formulation 42 2035-04-20

Related